Browse

You are looking at 71 - 80 of 2,740 items for

  • Refine by Content Type: Articles x
Clear All Modify Search
O. N. Ray Bignall II

You would be hard pressed to find a more capable, resilient, and diverse team of heroes than today's kidney health care workforce. From physicians and nurses to technicians and therapists…from researchers to clinicians to administrative professionals…our field is replete with talented individuals who bring their “all” to achieve equitable, high-quality patient care for the millions of those living with kidney diseases worldwide.

This issue of Kidney News is special, because in it, we are highlighting a key ingredient to achieving equitable, high-quality care for children and adults with kidney diseases: our diversity. We acknowledge the ongoing imperative to

Nupur N. Uppal and Steven Fishbane

In recent years, cardiologists have taken an approach to intravenous (IV) iron that is very different from that of nephrologists. In kidney disease, the role of IV iron is contemplated solely in relation to anemia, to improve hemoglobin, and as a support for erythropoietin-stimulating agent (ESA) therapy. This is a narrow view that fails to recognize that iron is not just important to manage anemia but that it is a basic health need for humans through its much broader significance for muscular function, energy creation, and storage as adenosine triphosphate.

In cardiology, this approach has led to a series of

Christel Wekon-Kemeni and Keisha L. Gibson

With more than 37 million people in the United States affected, chronic kidney disease (CKD) is arguably one of the largest threats to public health outside of the current COVID-19 pandemic. The American Society of Nephrology (ASN) aims to create a world without kidney diseases. To achieve this goal, health equity for all patient populations must be realized, which requires the vanquishing of racial and ethnic disparities in kidney health.

Much like the realities revealed by the COVID-19 pandemic, race-associated disparities in prevalence, morbidity, and mortality outcomes in people with CKD are glaring. These disparities stem directly from structural racism—a

The four-variable kidney failure risk equation (KFRE) is a better predictor of end stage kidney disease (ESKD) risk compared with the estimated glomerular filtration rate (eGFR) alone, with or without adjustment for race, reports a study in the Annals of Internal Medicine.

The researchers used data from the Chronic Renal Insufficiency Cohort to evaluate different eGFR equations for prediction of ESKD, defined as dialysis initiation or transplantation. The analysis included data on 3873 participants with chronic kidney disease (CKD), with a total of 13,902 2-year risk periods.

For each participant, eGFR was calculated using the CKD Epidemiology Collaboration

Karen Blum

Raising awareness of kidney diseases worldwide and empowering people living with them are the focus of campaigns launching in March.

One in three adults in the United States is at risk for kidney diseases. To shed light on the prevalence of this condition, the National Kidney Foundation (NKF), in honor of National Kidney Month, asks, “Are you the 33%?”

The slogan is part of a strategic digital campaign focused on reaching, educating, and empowering Americans who are Hispanic and of Black race, as well as individuals over age 35 or those who have one or more risk factors for kidney

Mary Jane Gore

Strive Health (Strive) has launched contracted partnership models under the Medicare program, Comprehensive Kidney Care Contracting (CKCC). Strive has partnered with 260 nephrology providers in five states in federally defined Kidney Contracting Entities (KCEs) to serve 8200 patients. Goals include delaying the progression of chronic kidney disease (CKD) to end stage kidney disease (ESKD) and supporting patients transitioning to dialysis and those going through the transplant process. Such efforts should reduce Medicare costs; a percentage of savings will return to the KCE partners.

Strive also announced that, to date, the company is managing 44,000 complex CKD and ESKD patients through

Solid-organ transplant recipients can maintain peripheral immunity for up to 6 months after SARS-CoV-2 infection—especially with greater clinical severity—reports a pre-proof paper in Kidney International.

The researchers evaluated serologic and functional T-cell and B-cell immune memory against major immunogenic SARS-CoV-2 antigens. The cross-sectional study included two groups of COVID-19 convalescent patients: 53 solid-organ transplant recipients (38 kidney recipients) and 49 immunocompetent patients.

In both groups, patients were classified as having severe COVID-19, requiring hospitalization and supplemental oxygen; mild COVID-19, not requiring hospitalization; or asymptomatic infection. Immunologic assessments included SARS-CoV-2-specific serologic memory and immunoglobulin G (IgG)-producing memory B cells

Stephanie Mahooty

In the United States, diabetes is the leading cause of kidney failure, and the prevalence of diabetes among American Indians and Alaskan Natives (AIs/ANs) is one of the highest among any racial and ethnic group. In the United States, diabetes accounts for 69% of new cases of end stage renal disease (ESRD; diabetes-associated ESRD [ESRD-D]) among the AI/AN population (1).

The roots of this disparity began in the 1950s and 1960s, when the epidemic of diabetes among the AI/AN population was soon followed by a dramatic increase in diabetic kidney disease and subsequent kidney failure, first described in

Harish Seethapathy

According to 2019 Association of American Medical Colleges (AAMC) data, international medical graduates (IMGs) comprise 23% of all actively practicing doctors in the United States (1). In nephrology, that number rises to 51% and in the coming years, is expected to grow, given that IMGs now make up nearly 60% of trainees entering the specialty. In the most recent fellowship match (appointment year [AY] 2022), 38% of all matched applicants were non-US IMGs, and most are likely to be on visas (2). The growing number of IMGs on visas (J-1 and H1-B; Table 1)

For patients with chronic kidney disease (CKD), discontinuing renin-angiotensin-aldosterone system inhibitors (RAASi) during episodes of hyperkalemia is associated with increased mortality and cardiovascular events, reports a pre-proof paper in the American Journal of Kidney Diseases.

The retrospective study included data on adult CKD patients with new episodes of RAASi-related hyperkalemia with a serum potassium level 5.5 mM or higher. Drawn from Canadian provincial databases, the analysis included 7200 patients in Manitoba and 71,290 patients in Ontario. The mean ages were 72.39 and 79.48 years, respectively. Several types of comorbidity were more frequent in the Manitoba cohort.

In response